Bioequivalence and Bioavailability Forum

Dear Depak,

I wouldn't do that, unless you have strong evidence that your drug does not show any pharmacokinetic interactions with granisetron. As a starter have a look at drugs.com. For a justification you must dig the original references. Remember: absence of evidence is not evidence of absence.
I would go for a scientific advice and/or a talk with the ethics committee in the planning stage of the study.